Bristol-Myers Squibb (NY:BMY)

58.81 -2.34 (-3.83%)

Official Closing Price Updated: 7:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

93 94 Next >

Stocks To Watch Today: 3M, BMY, And Coursera Inc. ↗

July 26, 2024

Several major companies reported quarterly earnings this week, with 3M, Bristol-Myers Squibb, and Coursera Inc. seeing significant stock price gains.

Via Talk Markets

Bristol Myers Squibb (BMY) Q2 2024 Earnings Call Transcript ↗

July 26, 2024

BMY earnings call for the period ending June 30, 2024.

Via The Motley Fool

Topics Earnings

Crude Oil Down Over 2%; Bristol Myers Squibb Posts Upbeat Q2 Results ↗

July 26, 2024

Via Benzinga

BMY Stock Earnings: Bristol-Myers Squibb Beats EPS, Beats Revenue for Q2 2024 ↗

July 26, 2024

BMY stock results show that Bristol-Myers Squibb beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Norfolk Southern Posts Upbeat Earnings, Joins Newell Brands, Charter Communications, 3M And Other Big Stocks Moving Higher On Friday ↗

July 26, 2024

Via Benzinga

Bristol Myers Squibb Earnings Easily Beat On Cost Cuts; Stock Jumps ↗

July 26, 2024

The drug giant also raised guidance.

Via Investor's Business Daily

A Glimpse Into The Expert Outlook On Bristol-Myers Squibb Through 4 Analysts ↗

July 22, 2024

Via Benzinga

Bristol Myers Squibb Witnesses Strong Demand For 'Newer Drugs' As Q2 Earnings Beat Expectations, Raises 2024 Profit Forecast ↗

July 26, 2024

Bristol Myers Squibb reported Q2 revenues of $12.2 billion, surpassing the consensus of $11.55B, driven by its Growth Portfolio and Eliquis. The company's adjusted EPS of $2.07 beat expectations of...

Via Benzinga

Topics Earnings

US Stocks Look To End Week On High Note As Nvidia Leads Mega-Caps Higher In Premarket Ahead Of Key Inflation Data ↗

July 26, 2024

After the severe pounding the tech space received in the past three sessions, it might be rebound time. However, any recovery will largely hinge on whether key inflation data confirms the continued...

Via Benzinga

Topics Economy

Bristol Myers Squibb Reports Second Quarter Financial Results for 2024

July 26, 2024

From Bristol Myers Squibb

Via Business Wire

What the Options Market Tells Us About Bristol-Myers Squibb ↗

July 18, 2024

Via Benzinga

High Dividend 50: Bristol-Myers Squibb ↗

July 16, 2024

This article will examine the prospects of Bristol-Myers as an investment opportunity.

Via Talk Markets

Bristol-Myers Squibb Unusual Options Activity For July 15 ↗

July 15, 2024

Via Benzinga

S&P 500, Nasdaq Settle Lower As Tech Stocks Continue To Falter: Greed Index In 'Fear' Zone ↗

July 26, 2024

Via Benzinga

Topics Stocks

Bristol-Myers Squibb, Deckers Outdoor And 3 Stocks To Watch Heading Into Friday ↗

July 26, 2024

Via Benzinga

DECK, SKX Higher After Earnings; PCE On Tap Friday ↗

July 25, 2024

It’s tough to get a firm handle on this market. One day it looks like a trading rotation into undervalued equities from big run-ups elsewhere, the next day it’s a major selloff across the board.

Via Talk Markets

2 High-Yield Dividend Stocks Billionaires Are Buying. Are They Right for You? ↗

July 25, 2024

Billionaires are buying these stocks, but that doesn't necessarily make them right for your portfolio.

Via The Motley Fool

Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation ↗

July 24, 2024

Guggenheim Partners initiated coverage on Alumis, highlighting its lead asset ESK-001, a TYK2 inhibitor for plaque psoriasis and systemic lupus erythematosus. With upcoming Phase 3 trials and no JAK...

Via Benzinga

Microsoft To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday ↗

July 23, 2024

Via Benzinga

AstraZeneca, Sanofi And Other Pharma Giants Pursue Chinese Deals Despite Rising US-China Strife ↗

July 23, 2024

The aim is to strengthen their drug pipelines and expand their presence in the world's second-largest pharmaceutical market.

Via Benzinga

3 Defensive Stocks to Shield Your Portfolio in July ↗

July 20, 2024

Fed Chair Jerome Powell’s cautious economic outlook adds to the allure of defensive stocks offering stable long-term returns

Via InvestorPlace

Topics Economy

7 Value Stocks to Buy at a 52-Week Low in July ↗

July 19, 2024

Bottom fishers and contrarians take note: each of these seven value stocks to buy is on sale after recently hitting new 52-week lows.

Via InvestorPlace

Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review ↗

July 19, 2024

The Nasdaq tumbled amid chip woes.

Via Investor's Business Daily

Tesla, Alphabet, GM, Ford Lead Earnings Parade This Week As Market Struggles To Sustain The Summer Rally ↗

July 21, 2024

The earnings parade continues this week with a slightly accelerated tempo as analysts brace for a healthy reporting season.

Via Benzinga

Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma

July 19, 2024

From Bristol Myers Squibb

Via Business Wire

Collect $2,000 in Dividends Per Year by Investing $35,000 in These 3 Stocks ↗

July 18, 2024

These stocks all pay more than four times the S&P 500 average.

Via The Motley Fool

Topics Stocks

US Bancorp Posts Upbeat Earnings, Joins Aehr Test Systems, Hancock Whitney And Other Big Stocks Moving Higher On Wednesday ↗

July 17, 2024

Via Benzinga

Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings' ↗

July 15, 2024

Via Benzinga

Topics Bankruptcy

Got $500? 2 No-Brainer Growth Stocks to Buy and Hold Forever ↗

July 15, 2024

These businesses are begging to be bought.

Via The Motley Fool

Week In Review: Foreseen Sells ADC Rights To France's Ipsen In $1 Billion Deal ↗

July 13, 2024

In other news, Sichuan Biokin Pharma has filed for an IPO on the Hong Kong Exchange; more on the Biosecure Act being pushed by US Speaker of the House Johnson.

Via Talk Markets

Topics Initial Public Offering

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

93 94 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.